Evidence map›Paper›PMID 40977734›Full record

ArticleFrontiers in immunology2025

miR-378a-5p targeting BRAF regulates CD4

Tingting Zhang, Hu Mu, Chuan Wang, Bingshuo Qian, Mingxing Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tingting Zhang *School of Clinical Medicine, Ningxia Medical University, Yinchuan, China.
Hu Mu *Key Laboratory of Common Infectious Disease Prevention and Control in Ningxia, Ningxia Medical University, Yinchuan, China.
Chuan WangKey Laboratory of Common Infectious Disease Prevention and Control in Ningxia, Ningxia Medical University, Yinchuan, China.
Bingshuo QianKey Laboratory of Common Infectious Disease Prevention and Control in Ningxia, Ningxia Medical University, Yinchuan, China.
Mingxing ZhuKey Laboratory of Common Infectious Disease Prevention and Control in Ningxia, Ningxia Medical University, Yinchuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cystic echinococcosis (CE) is a globally distributed zoonotic disease caused by Echinococcus granulosus (Eg) that often presents with insidious onset and asymptomatic progression. Although several Eg-based recombinant vaccines have been developed for the prevention of CE, our previous study demonstrated that recombinant Eg.P29 (r Methods: In this context, bioinformatics predictions and dual-luciferase reporter assays identified BRAF as a direct miR-378a-5p target, with downstream signaling involving the MAPK/ERK pathway. Results: Our research demonstrated that r Conclusion: In summary, our findings reveal that under the induction of r

Indexed as

Antigens, HelminthCD4-Positive T-LymphocytesCell DifferentiationEchinococcosisEchinococcus granulosusHelminth ProteinsMicroRNAsProto-Oncogene Proteins B-rafTh1 CellsAnimalsFemaleMAP Kinase Signaling SystemMiceAntigens, HelminthBraf protein, mouseHelminth ProteinsMicroRNAsMIRN378 microRNA, mouseProto-Oncogene Proteins B-rafBRAFCD4+T cells differentiationEchinococcus granulosus P29MAPK/ERK pathwaymiR-378a-5p

Identifiers

PMID40977734
PMCPMC12443751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.